Tus kws kho mob
P51R1-17 Updated: Accountable Care Organization Product and Network Name Changes
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 15, 2017
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 2671 - 2680 ntawm 4269
Tus kws kho mob
P60-17 2018 Renewal Changes Summary for Institutional Providers
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2017
Tus kws kho mob
P61-16 New Drug-Related Prior Authorization Criteria for Amitiza and Linzess
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 13, 2016
Tus kws kho mob
P52-16 DHS Guidelines for Mental Health-Targeted Case Management Services for MHCP Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 04, 2016
Tus kws kho mob
P63-17 New Drug-Related PA with Quantity Limit Criteria: Otezla (apremilast)
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 06, 2017
Tus kws kho mob
P63-16 Drug Related Prior Authorization Criteria Changes for Ampyra, H.P. Acthar Gel, Transmucosal Fentanyl, Growth Hormone, and Oral Pulmonary Arterial Hypertension Agents
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 20, 2016
Tus kws kho mob
P31-17 New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Thrombopoietin Receptor Agents
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 05, 2017
Tus kws kho mob
P57-17 Addition of Drugs to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Hlis Ntuj Tim 24, 2017
Tus kws kho mob
P39-17 Concurrent Review for Inpatient Hospital Services at Select Facilities
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 11, 2017
Tus kws kho mob
P62-16 EY Modifier for Platinum Blue Subscribers
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 13, 2016